Progress continues in prediction of the response to treatment of RA

In 2022, advances in the prediction of the response to treatment in rheumatoid arthritis resulted from gene-expression profiling in synovial biopsy samples, assessment of the expression of interferon-response genes in the blood, and the application of machine learning to patients’ clinical parameters and genetic variance. Key advances Gene expression in synovial biopsies predicts response to rituximab and tocilizumab and treatment-refractory state in rheumatoid arthritis (RA) 2 . Expression of interferon-response genes in the blood correlates with responsiveness to mixed DMARDs in early RA 3 . Machine learning applied to genotype data can be used for prediction of the response to methotrexate in early RA 4 .